Detecting recurrent passenger mutations in melanoma by targeted UV damage sequencing

Area of Science:

• Genomics
• Cancer Biology
• Molecular Oncology

Background:

• Melanoma sequencing reveals numerous recurrent mutations in coding and non-coding DNA, including known oncogenic drivers like BRAF, NRAS, and TERT promoter mutations.
• The molecular origins and functional significance of most identified melanoma mutations remain largely unknown.
• Understanding mutation drivers is crucial for targeted therapies and deciphering melanoma pathogenesis.

Purpose of the Study:

• To investigate the role of UV-induced DNA damage in shaping the melanoma mutation landscape.
• To identify specific mutation hotspots and their association with UV damage and transcription factor binding.
• To develop a method for distinguishing driver mutations from passenger mutations in melanoma.

Main Methods:

• Utilized CPD-capture-seq, a novel technique, to map UV-induced cyclobutane pyrimidine dimers (CPDs) at single nucleotide resolution.
• Analyzed recurrent mutation sites in melanoma, correlating them with CPD levels in UV-irradiated melanocytes.
• Examined the overlap between mutation hotspots, CPDs, and transcription factor binding sites, particularly E26 transformation-specific (ETS) factors.

Main Results:

• Many recurrent melanoma mutations, including previously identified drivers, were found at CPD hotspots in UV-exposed melanocytes.
• These hotspots frequently overlapped with binding sites for ETS transcription factors.
• Recurrent mutations in certain cancer gene promoters were not associated with elevated CPD levels.
• A subset of recurrent protein-coding mutations are likely driven by ETS-induced CPD hotspots.

Conclusions:

• UV-induced DNA damage and ETS transcription factors significantly influence the mutation landscape of melanoma.
• CPD-capture-seq provides a powerful method to differentiate driver mutations from passenger mutations caused by UV damage.
• This research offers new insights into melanoma etiology and potential therapeutic targets.